Fine tuning type I interferon responses

Cytokine and Growth Factor Reviews

Volumn 24, Issue 3, 2013, Pages 217-225

  Hertzog, Paul J ^a   Williams, Bryan R G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Antiviral; Innate Immunity; Interferons; Signal transduction; STATs

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; INTERFERON RECEPTOR; JANUS KINASE; PATTERN RECOGNITION RECEPTOR; PROMYELOCYTIC LEUKEMIA ZINC FINGER; PROTEIN KINASE R; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CYTOKINE RESPONSE; FLU LIKE SYNDROME; GENE EXPRESSION; GENE INDUCTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LEUKOPENIA; MYALGIA; NAUSEA; NEGATIVE FEEDBACK; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS INFECTION;

ANTIVIRAL; INNATE IMMUNITY; INTERFERONS; SIGNAL TRANSDUCTION; STATS;

ANIMALS; HUMANS; INTERFERON TYPE I; RECEPTORS, INTERFERON; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84881235615     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.04.002     Document Type: Review

References (119)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London. Series B: Biological Sciences 1957, 147:258-267.
2. Isaacs A., Edney M. Interference between inactive and active influenza viruses in the chick embryo. The Australian Journal of Experimental Biology and Medical Science 1950, 28:635-645.
3. Nagano Y., Kojima Y. Pouvoir immunisant du virus vaccinal inactivé par des rayons ultraviolets. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales 1954, 148:1700-1702.
4. Linnane A.W., Beilharz M.W., McMullen G.L., Macreadie I.G., Murphy M., Nisbet I.T., et al. Nucleotide sequence and expression in E. coli of a human interferon-alpha gene selected from a genomic library using synthetic oligonucleotides. Biochemistry International 1984, 8:725-732.
5. Nisbet I.T., Beilharz M.W., Hertzog P.J., Tymms M.J., Linnane A.W. Single amino acid substitutions at conserved residues of human interferon-alpha can effect antiviral specific activity. Biochemistry International 1985, 11:301-309.
6. Hertzog P.J., Emery P., Cheetham B.F., Mackay I.R., Linnane A.W. Interferons in rheumatoid arthritis: alterations in production and response related to disease activity. Clinical Immunology and Immunopathology 1988, 48:192-201.
7. Hertzog P.J., Wright A., Harris G., Linnane A.W., Mackay I.R. Intermittent interferonemia and interferon responses in multiple sclerosis. Clinical Immunology and Immunopathology 1991, 58:18-32.
8. Johns T.G., Mackay I.R., Callister K.A., Hertzog P.J., Devenish R.J., Linnane A.W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. Journal of the National Cancer Institute 1992, 84:1185-1190.
9. Owczarek C.M., Hwang S.Y., Holland K.A., Gulluyan L.M., Tavaria M., Weaver B., et al. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. The Journal of Biological Chemistry 1997, 272:23865-23870.
10. Hertzog P.J., Hwang S.Y., Holland K.A., Tymms M.J., Iannello R., Kola I. A gene on human chromosome 21 located in the region 21q22.2 to 21q22.3 encodes a factor necessary for signal transduction and antiviral response to type I interferons. The Journal of Biological Chemistry 1994, 269:14088-14093.
11. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:11284-11288.
12. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
13. Fenner J.E., Starr R., Cornish A.L., Zhang J.G., Metcalf D., Schreiber R.D., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nature Immunology 2006, 7:33-39.
14. Piganis R.A., De Weerd N.A., Gould J.A., Schindler C.W., Mansell A., Nicholson S.E., et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. The Journal of Biological Chemistry 2011, 286:33811-33818.
15. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 2004, 202:8-32.
16. de Weerd N.A., Samarajiwa S.A., Hertzog P.J. Type I, interferon receptors: biochemistry and biological functions. The Journal of Biological Chemistry 2007, 282:20053-20057.
17. Hervas-Stubbs S., Perez-Gracia J.L., Rouzaut A., Sanmamed M.F., Le Bon A., Melero I. Direct effects of type I interferons on cells of the immune system. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:2619-2627.
18. Hertzog P.J., O'Neill L.A., Hamilton J.A. The interferon in TLR signaling: more than just antiviral. Trends in Immunology 2003, 24:534-539.
19. Noppert S.J., Fitzgerald K.A., Hertzog P.J. The role of type I interferons in TLR responses. Immunology and Cell Biology 2007, 85:446-457.
20. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nature Reviews Immunology 2012, 12:125-135.
21. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
22. Swann J.B., Hayakawa Y., Zerafa N., Sheehan K.C., Scott B., Schreiber R.D., et al. Type I, IFN contributes to NK cell homeostasis, activation, and antitumor function. Journal of Immunology 2007, 178:7540-7549.
23. Crow M.K. Type I, interferon in systemic lupus erythematosus. Current Topics in Microbiology and Immunology 2007, 316:359-386.
24. Jonasch E., Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The Oncologist 2001, 6:34-55.
25. de Weerd N.A., Nguyen T. The interferons and their receptors - distribution and regulation. Immunology and Cell Biology 2012, 90:483-491.
26. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology 2010, 11:373-384.
27. Barbalat R., Lau L., Locksley R.M., Barton G.M. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nature Immunology 2009, 10:1200-1207.
28. Keating S.E., Baran M., Bowie A.G., Cytosolic DNA sensors regulating type I interferon induction. Trends in Immunology 2011, 32:574-581.
29. Cavlar T., Ablasser A., Hornung V. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunology and Cell Biology 2012, 90:474-482.
30. Tamura T., Yanai H., Savitsky D., Taniguchi T. The IRF, family transcription factors in immunity and oncogenesis. Annual Review of Immunology 2008, 26:535-584.
31. Prakash A., Smith E., Lee C.K., Levy D.E. Tissue-specific positive feedback requirements for production of type I interferon following virus infection. The Journal of Biological Chemistry 2005, 280:18651-18657.
32. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine 2012.
33. Okabe Y., Kawane K., Akira S., Taniguchi T., Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. The Journal of Experimental Medicine 2005, 202:1333-1339.
34. Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nature Genetics 2006, 38:917-920.
35. Crow Y.J., Leitch A., Hayward B.E., Garner A., Parmar R., Griffith E., et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nature Genetics 2006, 38:910-916.
36. Barbalat R., Ewald S.E., Mouchess M.L., Barton G.M. Nucleic acid recognition by the innate immune system. Annual Review of Immunology 2011, 29:185-214.
37. Hamilton J.A., Whitty G.A., Kola I., Hertzog P.J. Endogenous IFN-alpha beta suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha. Journal of Immunology 1996, 156:2553-2557.
38. Takayanagi H., Kim S., Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Research 2002, 4(Suppl 3):S227-S232.
39. Weiss G., Maaetoft-Udsen K., Stifter S.A., Hertzog P., Goriely S., Thomsen A.R., et al. MyD88 drives the IFN-beta response to Lactobacillus acidophilus in dendritic cells through a mechanism involving IRF1, IRF3, and IRF7. Journal of Immunology 2012, 189:2860-2868.
40. Fung K.Y., Mangan N.E., Cumming H., Horvat J.C., Mayall J.R., Stifter S.A., et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013, 339:1088-1092.
41. Garcia-Sastre A. Induction and evasion of type I interferon responses by influenza viruses. Virus Research 2011, 162:12-18.
42. Taylor K.E., Mossman K.L. Recent advances in understanding viral evasion of type I interferon. Immunology 2013, 138:190-197.
43. Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 1990, 60:225-234.
44. Novick D., Cohen B., Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994, 77:391-400.
45. Lutfalla G., Holland S.J., Cinato E., Monneron D., Reboul J., Rogers N.C., et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. The EMBO Journal 1995, 14:5100-5108.
46. Monroe K.M., McWhirter S.M., Vance R.E. Induction of type I interferons by bacteria. Cellular Microbiology 2010, 12:881-890.
47. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis and Rheumatism 2007, 56:3770-3783.
48. Thibault D.L., Graham K.L., Lee L.Y., Balboni I., Hertzog P.J., Utz P.J. Type I, interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Research & Therapy 2009, 11:R112.
49. Gough D.J., Messina N.L., Hii L., Gould J.A., Sabapathy K., Robertson A.P., et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biology 2010, 8:e1000361.
50. Thomas C., Moraga I., Levin D., Krutzik P.O., Podoplelova Y., Trejo A., et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
51. Tymms M.J., McInnes B., Waine G.J., Cheetham B.F., Linnane A.W. Functional significance of amino acid residues within conserved hydrophilic regions in human interferons-alpha. Antiviral Research 1989, 12:37-47.
52. Jaks E., Gavutis M., Uze G., Martal J., Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. Journal of Molecular Biology 2007, 366:525-539.
53. Cajean-Feroldi C., Nosal F., Nardeux P.C., Gallet X., Guymarho J., Baychelier F., et al. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry 2004, 43:12498-12512.
54. Bach E.A., Szabo S.J., Dighe A.S., Ashkenazi A., Aguet M., Murphy K.M., et al. Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science 1995, 270:1215-1218.
55. Yan H., Krishnan K., Lim J.T., Contillo L.G., Krolewski J.J. Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction. Molecular and Cellular Biology 1996, 16:2074-2082.
56. Domanski P., Fish E., Nadeau O.W., Witte M., Platanias L.C., Yan H., et al. A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. The Journal of Biological Chemistry 1997, 272:26388-26393.
57. Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:1603-1607.
58. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G., Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Molecular and Cellular Biology 1991, 11:2057-2065.
59. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
60. O'Shea J.J., Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012, 36:542-550.
61. Ragimbeau J., Dondi E., Alcover A., Eid P., Uze G., Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. The EMBO Journal 2003, 22:537-547.
62. Durbin J.E., Fernandez-Sesma A., Lee C.K., Rao T.D., Frey A.B., Moran T.M., et al. Type I, IFN modulates innate and specific antiviral immunity. Journal of Immunology 2000, 164:4220-4228.
63. Li X., Leung S., Kerr I.M., Stark G.R. Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling. Molecular and Cellular Biology 1997, 17:2048-2056.
64. Yang C.H., Shi W., Basu L., Murti A., Constantinescu S.N., Blatt L., et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. The Journal of Biological Chemistry 1996, 271:8057-8061.
65. Zhao W., Lee C., Piganis R., Plumlee C., de Weerd N., Hertzog P.J., et al. A conserved IFN-alpha receptor tyrosine motif directs the biological response to type I IFNs. Journal of Immunology 2008, 180:5483-5489.
66. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 2000, 288:2357-2360.
67. Mitani Y., Takaoka A., Kim S.H., Kato Y., Yokochi T., Tanaka N., et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes to Cells: Devoted to Molecular & Cellular Mechanisms 2001, 6:631-640.
68. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 2005, 5:375-386.
69. van Boxel-Dezaire A.H., Rani M.R., Stark G.R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372.
70. Ramana C.V., Gil M.P., Han Y., Ransohoff R.M., Schreiber R.D., Stark G.R. Stat1-independent regulation of gene expression in response to IFN-gamma. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6674-6679.
71. Yang C.H., Murti A., Pfeffer S.R., Kim J.G., Donner D.B., Pfeffer L.M. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. The Journal of Biological Chemistry 2001, 276:13756-13761.
72. Goh K.C., Haque S.J., Williams B.R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. The EMBO Journal 1999, 18:5601-5608.
73. Joshi S., Kaur S., Redig A.J., Goldsborough K., David K., Ueda T., et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12097-12102.
74. Kaur S., Sassano A., Majchrzak-Kita B., Baker D.P., Su B., Fish E.N., et al. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:7723-7728.
75. Kaur S., Sassano A., Dolniak B., Joshi S., Majchrzak-Kita B., Baker D.P., et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4808-4813.
76. Petricoin E.F., Ito S., Williams B.L., Audet S., Stancato L.F., Gamero A., et al. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature 1997, 390:629-632.
77. Ozato K. PLZF outreach: a finger in interferon's pie. Immunity 2009, 30:757-758.
78. Sadler A.J., Williams B.R.G. Interferon-inducible antiviral effectors. Nature Reviews Immunology 2008, 8:559-568.
79. Xu D., Holko M., Sadler A.J., Scott B., Higashiyama S., Berkofsky-Fessler W., et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009, 30:802-816.
80. Pioli P.D., Saleh A.M., El Fiky A., Nastiuk K.L., Krolewski J.J. Sequential proteolytic processing of an interferon-alpha receptor subunit by TNF-alpha converting enzyme and presenilins. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 2012, 32:312-325.
81. Hardy M.P., Owczarek C.M., Trajanovska S., Liu X., Kola I., Hertzog P.J. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001, 97:473-482.
82. Kumar K.G., Krolewski J.J., Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. The Journal of Biological Chemistry 2004, 279:46614-46620.
83. Malakhova O.A., Kim K.I., Luo J.K., Zou W., Kumar K.G., Fuchs S.Y., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. The EMBO Journal 2006, 25:2358-2367.
84. Min W., Pober J.S., Johnson D.R. Interferon induction of TAP1: the phosphatase SHP-1 regulates crossover between the IFN-alpha/beta and the IFN-gamma signal-transduction pathways. Circulation Research 1998, 83:815-823.
85. Coccia E.M., Uze G., Pellegrini S. Negative regulation of type I interferon signaling: facts and mechanisms. Cellular and Molecular Biology (Noisy-le-Grand, France) 2006, 52:77-87.
86. Gibbs V.C., Takahashi M., Aguet M., Chuntharapai A. A negative regulatory region in the intracellular domain of the human interferon-alpha receptor. The Journal of Biological Chemistry 1996, 271:28710-28716.
87. Baychelier F., Nardeux P.C., Cajean-Feroldi C., Ermonval M., Guymarho J., Tovey M.G., et al. Involvement of the Gab2 scaffolding adapter in type I interferon signalling. Cellular Signalling 2007, 19:2080-2087.
88. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nature Reviews Immunology 2005, 5:593-605.
89. Ezell S.A., Polytarchou C., Hatziapostolou M., Guo A., Sanidas I., Bihani T., et al. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E613-E621.
90. Tisserand J., Khetchoumian K., Thibault C., Dembele D., Chambon P., Losson R. Tripartite motif 24 (Trim24/Tif1alpha) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor alpha (Raralpha) inhibition. The Journal of Biological Chemistry 2011, 286:33369-33379.
91. Yoshida K., Yamamoto K., Kohno T., Hironaka N., Yasui K., Kojima C., et al. Active repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory factor-4. International Immunology 2005, 17:1463-1471.
92. Sharma B., Joshi S., Sassano A., Majchrzak B., Kaur S., Aggarwal P., et al. Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. The Journal of Biological Chemistry 2012, 287:42352-42360.
93. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature Cell Biology 2009, 11:228-234.
94. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Research 2011, 39:D152-D157.
95. Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N., Basyuk E., et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005, 309:1573-1576.
96. Gantier M.P., Sadler A.J., Williams B.R. Fine-tuning of the innate immune response by microRNAs. Immunology and Cell Biology 2007, 85:458-462.
97. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Developmental Biology 2007, 302:1-12.
98. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
99. Bruni R., Marcantonio C., Tritarelli E., Tataseo P., Stellacci E., Costantino A., et al. An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones. BMC Genomics 2011, 12:485.
100. McCoy C.E. The role of miRNAs in cytokine signaling. Frontiers in Bioscience 2011, 16:2161-2171.
101. Wang P., Hou J., Lin L., Wang C., Liu X., Li D., et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. Journal of Immunology 2010, 185:6226-6233.
102. Papadopoulou A.S., Dooley J., Linterman M.A., Pierson W., Ucar O., Kyewski B., et al. The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor. Nature Immunology 2012, 13:181-187.
103. Der S.D., Zhou A., Williams B.R., Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:15623-15628.
104. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., et al. Functional classification of interferon-stimulated genes identified using microarrays. Journal of Leukocyte Biology 2001, 69:912-920.
105. Samarajiwa S.A., Forster S., Auchettl K., Hertzog P.J. INTERFEROME, the database of interferon regulated genes. Nucleic Acids Research 2009, 37:D852-D857.
106. Hertzog P., Forster S., Samarajiwa S. Systems biology of interferon responses. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 2011, 31:5-11.
107. Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Research 2013, 41:D1040-D1046.
108. Harman A.N., Lai J., Turville S., Samarajiwa S., Gray L., Marsden V., et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 2011, 118:298-308.
109. Zhao M., Zhang J., Phatnani H., Scheu S., Maniatis T. Stochastic expression of the interferon-beta gene. PLoS Biology 2012, 10:e1001249.
110. Thomas K.E., Galligan C.L., Newman R.D., Fish E.N., Vogel S.N. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. The Journal of Biological Chemistry 2006, 281:31119-31130.
111. Carpick B.W., Graziano V., Schneider D., Maitra R.K., Lee X., Williams B.R.G. Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA. Journal of Biological Chemistry 1997, 272:9510-9516.
112. Ito T., Yang M., May W.S. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. Journal of Biological Chemistry 1999, 274:15427-15432.
113. Patel C.V., Handy I., Goldsmith T., Patel R.C. PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. Journal of Biological Chemistry 2000, 275:37993-37998.
114. Patel R.C., Sen G.C. PACT, a protein activator of the interferon-induced protein kinase, PKR. The EMBO Journal 1998, 17:4379-4390.
115. Goh K.C., deVeer M.J., Williams B.R. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. The EMBO Journal 2000, 19:4292-4297.
116. Kumar A., Yang Y.L., Flati V., Der S., Kadereit S., Deb A., et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. The EMBO Journal 1997, 16:406-416.
117. Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F. PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex. Molecular and Cellular Biology 2000, 20:4532-4542.
118. Jiang Z., Zamanian-Daryoush M., Nie H., Silva A.M., Williams B.R., Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. The Journal of Biological Chemistry 2003, 278:16713-16719.
119. Irving A.T., Wang D., Vasilevski O., Latchoumanin O., Kozer N., Clayton A.H., et al. Regulation of actin dynamics by protein kinase R control of gelsolin enforces basal innate immune defense. Immunity 2012, 36:795-806.